Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.4 CURRENCY
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET RANKING ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT ON BLOOD SCREENING MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
5.4 SUPPLY/VALUE CHAIN ANALYSIS
5.5 PORTER'S FIVE FORCES ANALYSIS
5.6 ECOSYSTEM ANALYSIS OF THE GLOBAL BLOOD SCREENING MARKET
5.7 TARIFF & REGULATORY LANDSCAPE
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
5.10 KEY CONFERENCES & EVENTS IN 2023-2024
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.12 TECHNOLOGY ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 IMPORT SCENARIO
5.13.2 EXPORT SCENARIO
5.14 CASE STUDY ANALYSIS
6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.2.1 NAT REAGENTS & KITS
6.2.1.1 ENZYMES AND POLYMERASES
6.2.1.2 STANDARDS AND CONTROLS
6.2.1.3 PROBES AND PRIMERS
6.2.1.4 BUFFERS, NUCLEOTIDES & SOLUTIONS
6.2.1.5 LABELING & DETECTION REAGENTS
6.2.2 ELISA REAGENTS & KITS
6.2.2.1 IMMUNOSORBENTS
6.2.2.2 CONTROLS
6.2.2.3 CONJUGATES
6.2.2.4 SUBSTRATES
6.2.2.5 SAMPLE DILUENTS & WASH SOLUTIONS
6.2.3 OTHER REAGENTS & KITS
6.3 INSTRUMENTS
6.3.1 RENTAL PURCHASE
6.3.2 OUTRIGHT PURCHASE
6.4 SOFTWARE & SERVICES
8 BLOOD SCREENING MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 NUCLEIC ACID TEST (NAT)
8.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA)
8.2.2 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR)
8.3 SEROLOGY/IMMUNOASSAY
8.3.1 CHEMILUMINESCENT IMMUNOASSAYS (CLIA)
8.3.2 FLUORESCENT IMMUNOASSAYS (FIA)
8.3.3 COLORIMETRIC IMMUNOASSAYS (CIA)/ ENZYME-LINKED IMMUNOASSAYS (ELISA)
8.4 RAPID TESTS
8.5 WESTERN BLOT ASSAYS
8.6 NEXT-GENERATION SEQUENCING (NGS)
9 BLOOD SCREENING MARKET, BY END USER
9.1 INTRODUCTION
9.2 BLOOD BANKS
9.3 HOSPITALS
10 BLOOD SCREENING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 RECESSION IMPACT
10.2.2 US
10.2.3 CANADA
10.3 EUROPE
10.3.1 RECESSION IMPACT
10.3.2 GERMANY
10.3.3 UK
10.3.4 FRANCE
10.3.5 ITALY
10.3.7 SPAIN
10.3.8 ROE
10.4 ASIA PACIFIC
10.4.1 RECESSION IMPACT
10.4.2 CHINA
10.4.4 JAPAN
10.4.5 INDIA
10.4.6 AUSTRALIA
10.4.7 ROAPAC
10.5 LATIN AMERICA
10.5.1 RECESSION IMPACT
10.5.2 BRAZIL
10.5.3 MEXICO
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 MARKET SHARE ANALYSIS
11.4 REVENUE SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING
11.7 COMPETITIVE SCENARIO AND TRENDS
11.7.1 PRODUCT LAUNCHES & APPROVALS
11.7.2 DEALS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
12.1.2 GRIFOLS
12.1.3 THERMO FISHER SCIENTIFIC, INC.
12.1.4 ABBOTT LABORATORIES
12.1.5 BIO-RAD LABORATORIES, INC.
12.1.6 REVVITY (EARLIER KNOWN AS PERKINELMER, INC.)
12.1.7 BIOMÉRIEUX SA
12.1.8 MINDRAY
12.1.9 SIEMENS HEALTHINEERS AG
12.1.10 DANAHER CORPORATION (BECKMAN COULTER, INC)
12.2 OTHER PLAYERS
12.2.1 DIASORIN
12.2.2 BECTON, DICKINSON AND COMPANY
12.2.3 QUIDELORTHO CORPORATION
12.2.4 GE HEALTHCARE (WESTERN BLOTTING)
12.2.5 MERCK MILLIPORE (WESTERN BLOTTING)
12.2.6 BIO-TECHNE CORPORATION (WESTERN BLOTTING)
12.2.7 TRINITY BIOTECH
12.2.8 MACCURA BIOTECHNOLOGY CO., LTD.
12.2.9 ENZO BIOCHEM, INC.
12.2.10 J. MITRA & CO. PVT. LTD.
12.2.11 GFE
12.2.12 IMMUCOR, INC.
12.2.13 CELLABS
12.2.14 ABNOVA CORPORATION
12.2.15 TULIP DIAGNOSTICS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKET'S SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
Note:
Details on financials may not be captured in case of privately held companies that do not disclose their revenues in public domain.
Top 20-30 Companies in the market (Blood Screening Market) will be profiled.
Market segmentation might be updated as per the research findings.
The market size will be given in terms of value (USD Million). The historical year considered for the study would be 2021, with base year as 2022, estimated year would be 2023 and forecast period would be 2023-2028.